1. Academic Validation
  2. Helicobacter pylori CagA promotes gastric cancer immune escape by upregulating SQLE

Helicobacter pylori CagA promotes gastric cancer immune escape by upregulating SQLE

  • Cell Death Dis. 2025 Jan 14;16(1):17. doi: 10.1038/s41419-024-07318-w.
Sifan Liu # 1 Nan Zhang # 2 Xu Ji 1 Shuyue Yang 1 Zheng Zhao 1 Peng Li 3
Affiliations

Affiliations

  • 1 Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory for Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Digestive Disease Center, Beijing, 100050, China.
  • 2 Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory for Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Digestive Disease Center, Beijing, 100050, China. zhangnan_2020@126.com.
  • 3 Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory for Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Digestive Disease Center, Beijing, 100050, China. lipeng@ccmu.edu.cn.
  • # Contributed equally.
Abstract

Helicobacter pylori (H. pylori) Infection is a well-established risk factor for gastric Cancer, primarily due to its virulence factor, cytotoxin-associated gene A (CagA). Although PD-L1/PD-1-mediated immune evasion is critical in Cancer development, the impact of CagA on PD-L1 regulation remains unclear. This study revealed that H. pylori CagA upregulated squalene epoxidase (SQLE) expression, a key Enzyme in the Cholesterol biosynthesis pathway. Elevated SQLE activity increased cellular palmitoyl-CoA levels, enhancing PD-L1 palmitoylation while decreasing its ubiquitination. This ultimately increases PD-L1 stability, suppressing T cell activity and facilitating immune evasion in gastric Cancer. In summary, our findings highlight the crucial role of the CagA-SQLE-PD-L1 axis in gastric Cancer progression, suggesting potential therapeutic strategies for targeting CagA-positive gastric Cancer.

Figures
Products